HOME >> BIOLOGY >> NEWS
Although controversial, stem cell therapies exhibit potential in biotechnology markets

SAN ANTONIO June 11, 2002 Stem cells have enormous potential for repairing damage to the body caused by disease, injury, or aging. When introduced into an injured area of a patient, a stem cell could survive and repopulate the region with different types of cells, forming normal tissue.

Stem cells also offer the prospect of treating many inherited diseases caused
by a single, defective gene. Though other
treatments are available, such as gene therapy,
the longevity of benefits from stem cell treatment
provides a tantalizing option for researchers.

Heated controversy has arisen over the ethics of using embryonic stem cells, extracted from either very early embryos or fetuses. The United States has now limited stem cell use to a relatively small number of existing cell lines.

Stem cells are pluripotent, possessing the ability to differentiate into other types of cells. However, other stem cells, which are not derived from embryos and not completely pluripotent, have great potential to differentiate into cells, redeveloping certain tissues or organs. Hematopoietic cells, found in the bone marrow and umbilical cord, for example, can differentiate into all types of blood cells.

In order to make stem cell therapy a reality, it is not only necessary to have suitable stem cells, but also to know how to direct their differentiation and formation of new tissues. Scientists have begun to make new discoveries concerning genes and their protein products that govern various types of cell differentiation, but additional research is imperative.

Stem cell therapies are inherently more complicated than drug treatment, providing a stumbling block for stem cell therapy in the marketplace. However, while stem cell therapy remains costly, it will almost certainly last for several years before the procedure must be repeated. A low annual cost of $2500 per patient for stem cell therapy products at the manufacturers l
'"/>

Contact: Julia Rowell
jrowell@frost.com
210-247-3870
Technical Insights
12-Jun-2002


Page: 1 2

Related biology news :

1. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
2. Serotonin metabolites in mollusks suggest pathways for human therapies
3. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies
4. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
5. Insight into transplant rejection might lead to novel prevention therapies
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Insights on stroke from the peripheral blood suggest ways to develop markers and therapies
8. Novel approaches to current cellular therapies continue progress toward disease prevention
9. Novel therapies show promise against myeloid leukemia
10. Scientists discover potential approaches to enhance existing cancer therapies
11. Clock cells, tumor suicide, tailored therapies among subjects of AACR-NCI-EORTC Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
Cached News: